US Patent

US11951111 — Immediate release multilayer tablet

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2041-11-12 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using tablets that contain olanzapine and samidorphan for treating certain disorders.

USPTO Abstract

Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.

Drugs covered by this patent

Zyprexa (olanzapine) · Eli Lilly

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3886`	—	Zyprexa
`U-3886`	—	Zyprexa
`U-3886`	—	Zyprexa
`U-3886`	—	Zyprexa

Patent Metadata

Patent number: US11951111
Jurisdiction: US
Classification: Method of Use
Expires: 2041-11-12
Drug substance claim: No
Drug product claim: No
Assignee: Alkermes Pharma Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.